Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis

被引:238
作者
Bruckert, Eric [1 ]
Labreuche, Julien [2 ,3 ,4 ,5 ]
Amarenco, Pierre [2 ,3 ,4 ,5 ]
机构
[1] Univ Paris 06, Pitie Salpetriere Univ Hosp, Dept Endocrinol, F-75651 Paris, France
[2] INSERM, U698, Paris 7, France
[3] Denis Diderot Univ, Paris 7, France
[4] Hop Xavier Bichat, Dept Neurol, Paris, France
[5] Hop Xavier Bichat, Stroke Ctr, Paris, France
关键词
Nicotinic acid; Cardiovascular disease; Stroke; Atherosclerosis; Intima media thickness; Meta-analysis; DENSITY-LIPOPROTEIN-CHOLESTEROL; CORONARY-HEART-DISEASE; EXTENDED-RELEASE NIACIN; SECONDARY PREVENTION; CAROTID ATHEROSCLEROSIS; MEDIA THICKNESS; HDL-CHOLESTEROL; RISK-FACTOR; REDUCTION; THERAPY;
D O I
10.1016/j.atherosclerosis.2009.12.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: High-density lipoprotein cholesterol (HDL-C) concentration is a strong predictor of cardiovascular events in both naive and statin-treated patients. Nicotinic acid is an attractive option for decreasing residual risk in statin-treated or statin-intolerant patients since it increases HDL-C by up to 20% and decreases low-density lipoprotein cholesterol and lipoprotein(a) plasma concentrations. Methods: We performed a computerized PubMed literature search that focused on clinical trials evaluating niacin, alone or in combination with other lipid-lowering drugs, published between January 1966 and August 2008. Results: Among 587 citations, 29 full articles were read and 14 were eligible for inclusion. Overall 11 randomized controlled trials enrolled 2682 patients in the active group and 3934 in the control group. In primary analysis, niacin significantly reduced major coronary events (relative odds reduction = 25%, 95% CI 13, 35), stroke (26%, 95% CI = 8, 41) and any cardiovascular events (27%, 95% CI = 15, 37). Except for stroke, the pooled between-group difference remained signi. cant in sensitivity analysis excluding the largest trial. In comparison with the non-niacin group, more patients in the niacin group had regression of coronary atherosclerosis (relative increase = 92%, 95% CI = 39, 67) whereas the rate of patients with progression decreased by 41%, 95% CI = 25, 53. Similar effects of niacin were found on carotid intima thickness with a weighted mean difference in annual change of -17 mu m/year (95% CI =-22, -12). Conclusions: Although the studies were conducted before statin therapy become standard care, and mostly in patients in secondary prevention, with various dosages of nicotinic acid 1-3 g/day, this meta-analysis found positive effects of niacin alone or in combination on all cardiovascular events and on atherosclerosis evolution. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:353 / 361
页数:9
相关论文
共 52 条
[1]   Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy [J].
Airan-Javia, Subha L. ;
Wolf, Ronald L. ;
Wolfe, Megan L. ;
Tadesse, Mahlet ;
Mohler, Emile ;
Reilly, Muredach P. .
AMERICAN HEART JOURNAL, 2009, 157 (04) :687.e1-687.e8
[2]   High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review [J].
Amarenco, Pierre ;
Labreuche, Julien ;
Touboul, Pierre-Jean .
ATHEROSCLEROSIS, 2008, 196 (02) :489-496
[3]   Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial [J].
Amarenco, Pierre ;
Goldstein, Larry B. ;
Messig, Michael ;
O'Neill, Blair J. ;
Callahan, Alfred, III ;
Sillesen, Henrik ;
Hennerici, Michael G. ;
Zivin, Justin A. ;
Welch, K. M. A. .
STROKE, 2009, 40 (07) :2486-2492
[4]   Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial [J].
Amarenco, Pierre ;
Goldstein, Larry B. ;
Callahan, Alfred, III ;
Sillesen, Henrik ;
Hennerici, Michael G. ;
O'Neill, Blair J. ;
Rudolph, Amy E. ;
Simunovic, Lisa ;
Zivin, Justin A. ;
Welch, K. M. A. .
ATHEROSCLEROSIS, 2009, 204 (02) :515-520
[5]  
[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360
[6]   Lipoprotein(a): A unique risk factor for cardiovascular disease [J].
Anuurad, Erdembileg ;
Boffa, Michael B. ;
Koschinsky, Marlys L. ;
Berglund, Lars .
CLINICS IN LABORATORY MEDICINE, 2006, 26 (04) :751-+
[7]   The safety of statins in clinical practice [J].
Armitage, Jane .
LANCET, 2007, 370 (9601) :1781-1790
[8]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[9]   HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].
Barter, Philip ;
Gotto, Antonio M. ;
LaRosa, John C. ;
Maroni, Jaman ;
Szarek, Michael ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Bittner, Vera ;
Fruchart, Jean-Charles .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310
[10]   Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials [J].
Birjmohun, RS ;
Hutten, BA ;
Kastelein, JJP ;
Stroes, ESG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :185-197